Here, our in vivo data demonstrated that silencing B4GALNT1 significantly enhances the tumor-killing efficiency of the PD-1 targeting strategy, indicating that B4GALNT1 is a strong candidate for combined immune therapy approaches. This evidence concerns the gene PDCD1 and neoplasm.